Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

Colorectal Cancer Clinical Trial

Official title:

Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03831698
• Other study ID #: IIT-2018-Omega3-CRC-Prev
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: February 6, 2019
• Est. completion date: August 2024

Study information

• Verified date: May 2023
• Source: University of Kansas Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot study aimed at assessing the effects of moderate dose omega-3-acid ethyl esters capsules (generic Lovaza) on molecular, and intestinal microbiota changes in participants at high risk for colorectal cancer. The study will be a single arm, open label study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 21
• Est. completion date: August 2024
• Est. primary completion date: June 8, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ability of participant or Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
• Candidate for elective endoscopy procedure
• Participants with known Lynch Syndrome
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
• Willing to undergo a colonoscopy and biopsy at baseline and another colonoscopy and biopsy at 12 months visit.
• Participants taking Aspirin for chemoprevention must agree to stop it for at least 4 weeks prior to study entry and throughout the trial period
• Adequate organ and marrow function
• Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use two forms of adequate contraception (hormonal AND barrier method of birth control) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she should inform her treating physician immediately.
• Men of child-bearing potential must not father a child or donate sperm while on this study and for 90 days after their last study treatment.

Exclusion Criteria:

• Current or anticipated use of other investigational agents while participating in this study.
• Psychiatric illness/social situations that could limit compliance with study requirements.
• Pregnant or breast feeding.
• Familial adenomatous polyposis, Putz-Jeghers disease, ulcerative colitis, or Crohn's disease.
• Previous or known active malignancies, except non-melanoma skin cancers, unless curatively treated and with no evidence of recurrence for more than 5 years
• Current use of anticoagulation therapy
• Current use of therapeutic doses of aspirin for reasons other than chemoprevention
• Use of omega 3 fatty acids or flaxseed supplements within 4 weeks before this study's screening/baseline colonoscopy
• Use of high dose omega 3 fatty acids within the past 3 months prior to study baseline/screening
• Current, regular use of non-steroidal anti-inflammatory drugs (NSAIDS)
• Allergy to fish and/or fish products
• Uncontrolled infectious disease
• Malabsorption syndrome, disease affecting gastrointestinal function, or previous resection of the stomach or small bowel.
• Unable to swallow and retain oral medication

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• Colorectal Neoplasms, Hereditary Nonpolyposis
• Lynch Syndrome
• Syndrome

Intervention

Drug:
• Omega-3 fatty acid ethyl esters (2 gram)
Omega-3 fatty acid ethyl esters (2 gram)

Locations

Country	Name	City	State
United States	The University of Kansas Cancer Center, Westwood Campus	Kansas City	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
University of Kansas Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Retention rate of participants	Feasibility is defined as at least 80% retention rate	12 months
Secondary	Proportion of participants with treatment-related adverse events in each arm.	Measured by Common Terminology Criteria Adverse Events (CTCAE) V5.0	12 months